Zentiva Seeks RON100M Profit and RON850M Sales in 2023

04.06.2023 By Georgiana Mihalache

Zentiva (SCD.RO), the largest pharmaceutical company listed on the Bucharest Stock Exchange, though with a low free float of merely 4%, is aiming for net sales of RON856 million and RON101.7 million net profit in 2023, according to the spending and revenue budget submitted to shareholders to vote.

To read the full story, please login. Not a member? Subscribe here.

Reveal Romania! Business news & views.
Find out all you need by reading the entire story
To invest in Romania, you need to find out about its opportunities.
To close a strategic partnership with a Romanian company, you need to learn about its market position and whether it is a trustworthy partner
To grow here, you need to be informed

Subscribe now
Only 50 euros/month (VAT not included)
Get access to reports, news and statistics in the main sectors of Romania’s economy. Follow the strategic moves of companies operating in Romania. We will keep you updated on the latest business events.
Contact: E: newsroom@zfenglish.com (newsroom), marketing@zfenglish.com (Marketing & PR), sales@zfenglish.com (subscriptions)
T: 0040-318.256.431 (Newsroom)
0040-318.256.158, 0040-318.256.408 (Subscriptions Department)
0040-318.256.469, 0040-318.256.470 (Advertising Sales Department)
0040-318.256.427, 0040-318.256.129 (Marketing & PR)

LOGIN / Lost password?

 
Keywords:
zentiva
, revenue
, profit
, target
, growth